{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:18:21Z","timestamp":1790788701974,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T00:00:00Z","timestamp":1492992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T00:00:00Z","timestamp":1492992000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1038\/bmt.2017.23","type":"journal-article","created":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T14:23:26Z","timestamp":1493043806000},"page":"1113-1119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study"],"prefix":"10.1038","volume":"52","author":[{"given":"E","family":"Schorb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C P","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Fritsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Isbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Tzalavras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Witherall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Choquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O","family":"Kuittinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"De-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Cwynarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Houillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Hoang-Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Touitou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Cassoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-P","family":"Marolleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Tamburini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Houot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Delwail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Illerhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Soussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Kasenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,24]]},"reference":[{"key":"BFbmt201723_CR1","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1002\/cncr.21481","volume":"104","author":"KS Panageas","year":"2005","unstructured":"Panageas KS, Elkin EB, DeAngelis LM, Ben-Porat L, Abrey LE . Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis. Cancer 2005; 104: 2466\u20132472.","journal-title":"Cancer"},{"key":"BFbmt201723_CR2","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/cncr.10851","volume":"95","author":"JE Olson","year":"2002","unstructured":"Olson JE, Janney CA, Rao RD, Cerhan JR, Kurtin PJ, Schiff D et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 2002; 95: 1504\u20131510.","journal-title":"Cancer"},{"key":"BFbmt201723_CR3","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.surneu.2006.05.055","volume":"66","author":"K Makino","year":"2006","unstructured":"Makino K, Nakamura H, Kino T, Takeshima H, Kuratsu J . Rising incidence of primary central nervous system lymphoma in Kumamoto, Japan. Surg Neurol 2006; 66: 503\u2013506.","journal-title":"Surg Neurol"},{"key":"BFbmt201723_CR4","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1200\/JCO.2000.18.17.3144","volume":"18","author":"LE Abrey","year":"2000","unstructured":"Abrey LE, Yahalom J, DeAngelis LM . Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000; 18: 3144\u20133150.","journal-title":"J Clin Oncol"},{"key":"BFbmt201723_CR5","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1634\/theoncologist.2008-0236","volume":"14","author":"M Sierra del Rio","year":"2009","unstructured":"Sierra del Rio M, Rousseau A, Soussain C, Ricard D, Hoang-Xuan K . Primary CNS lymphoma in immunocompetent patients. Oncologist 2009; 14: 526\u2013539.","journal-title":"Oncologist"},{"key":"BFbmt201723_CR6","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/annonc\/mdi075","volume":"16","author":"K Jahnke","year":"2005","unstructured":"Jahnke K, Korfel A, Martus P, Weller M, Herrlinger U, Schmittel A et al. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol 2005; 16: 445\u2013449.","journal-title":"Ann Oncol"},{"key":"BFbmt201723_CR7","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1002\/cncr.22907","volume":"110","author":"KS Panageas","year":"2007","unstructured":"Panageas KS, Elkin EB, Ben-Porat L, Deangelis LM, Abrey LE . Patterns of treatment in older adults with primary central nervous system lymphoma. Cancer 2007; 110: 1338\u20131344.","journal-title":"Cancer"},{"key":"BFbmt201723_CR8","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1016\/S2352-3026(15)00074-5","volume":"2","author":"A Omuro","year":"2015","unstructured":"Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V et al. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. Lancet Haematol 2015; 2: e251\u2013e259.","journal-title":"Lancet Haematol"},{"key":"BFbmt201723_CR9","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1093\/annonc\/mdv076","volume":"26","author":"B Kasenda","year":"2015","unstructured":"Kasenda B, Ferreri AJ, Marturano E, Forst D, Bromberg J, Ghesquieres H et al. First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)-a systematic review and individual patient data meta-analysis. Ann Oncol 2015; 26: 1305\u20131313.","journal-title":"Ann Oncol"},{"key":"BFbmt201723_CR10","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1200\/JCO.2006.06.2117","volume":"24","author":"G Illerhaus","year":"2006","unstructured":"Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006; 24: 3865\u20133870.","journal-title":"J Clin Oncol"},{"key":"BFbmt201723_CR11","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3324\/haematol.11771","volume":"93","author":"G Illerhaus","year":"2008","unstructured":"Illerhaus G, Muller F, Feuerhake F, Schafer AO, Ostertag C, Finke J . High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 2008; 93: 147\u2013148.","journal-title":"Haematologica"},{"key":"BFbmt201723_CR12","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","volume":"125","author":"A Omuro","year":"2015","unstructured":"Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood 2015; 125: 1403\u20131410.","journal-title":"Blood"},{"key":"BFbmt201723_CR13","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.3324\/haematol.2011.060434","volume":"97","author":"C Soussain","year":"2012","unstructured":"Soussain C, Choquet S, Fourme E, Delgadillo D, Bouabdallah K, Ghesquieres H et al. Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. Haematologica 2012; 97: 1751\u20131756.","journal-title":"Haematologica"},{"key":"BFbmt201723_CR14","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1200\/JCO.2007.13.5533","volume":"26","author":"C Soussain","year":"2008","unstructured":"Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol 2008; 26: 2512\u20132518.","journal-title":"J Clin Oncol"},{"key":"BFbmt201723_CR15","doi-asserted-by":"crossref","unstructured":"Illerhaus G KB, Ihorst G, Egerer G, Lamprecht M, Keller U et al. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematol 2016 in press.","DOI":"10.1016\/S2352-3026(16)30050-3"},{"key":"BFbmt201723_CR16","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1212\/WNL.0b013e318297eeba","volume":"81","author":"ND Doolittle","year":"2013","unstructured":"Doolittle ND, Korfel A, Lubow MA, Schorb E, Schlegel U, Rogowski S et al. Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma. Neurology 2013; 81: 84\u201392.","journal-title":"Neurology"},{"key":"BFbmt201723_CR17","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1093\/annonc\/mdp529","volume":"21","author":"H Ghesquieres","year":"2010","unstructured":"Ghesquieres H, Ferlay C, Sebban C, Perol D, Bosly A, Casasnovas O et al. Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Ann Oncol 2010; 21: 842\u2013850.","journal-title":"Ann Oncol"},{"key":"BFbmt201723_CR18","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1200\/JCO.2003.11.036","volume":"21","author":"K Hoang-Xuan","year":"2003","unstructured":"Hoang-Xuan K, Taillandier L, Chinot O, Soubeyran P, Bogdhan U, Hildebrand J et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 2003; 21: 2726\u20132731.","journal-title":"J Clin Oncol"},{"key":"BFbmt201723_CR19","doi-asserted-by":"publisher","first-page":"534","DOI":"10.3324\/haematol.2014.108472","volume":"100","author":"EJ Pulczynski","year":"2015","unstructured":"Pulczynski EJ, Kuittinen O, Erlanson M, Hagberg H, Fossa A, Eriksson M et al. Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group. Haematologica 2015; 100: 534\u2013540.","journal-title":"Haematologica"},{"key":"BFbmt201723_CR20","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1016\/j.ijrobp.2006.03.061","volume":"65","author":"NN Laack","year":"2006","unstructured":"Laack NN, Ballman KV, Brown PB, O'Neill BP . North Central Cancer Treatment G. Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: results of North Central Cancer Treatment Group (NCCTG) 96-73-51. Int J Radiat Oncol Biol Phys 2006; 65: 1429\u20131439.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"BFbmt201723_CR21","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1002\/ajh.23812","volume":"89","author":"G Olivier","year":"2014","unstructured":"Olivier G, Clavert A, Lacotte-Thierry L, Gardembas M, Escoffre-Barbe M, Brion A et al. A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial. Am J Hematol 2014; 89: 1024\u20131029.","journal-title":"Am J Hematol"},{"key":"BFbmt201723_CR22","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1093\/annonc\/mdv002","volume":"26","author":"B Kasenda","year":"2015","unstructured":"Kasenda B, Schorb E, Fritsch K, Finke J, Illerhaus G . Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma\u2014a long-term follow-up study. Ann Oncol 2015; 26: 608\u2013611.","journal-title":"Ann Oncol"},{"key":"BFbmt201723_CR23","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3324\/haematol.2012.076075","volume":"98","author":"E Schorb","year":"2013","unstructured":"Schorb E, Kasenda B, Atta J, Kaun S, Morgner A, Hess G et al. Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. Haematologica 2013; 98: 765\u2013770.","journal-title":"Haematologica"},{"key":"BFbmt201723_CR24","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","volume":"3","author":"AJ Ferreri","year":"2016","unstructured":"Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol 2016; 3: e217\u2013e227.","journal-title":"Lancet Haematol"},{"key":"BFbmt201723_CR25","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 4184\u20134190.","journal-title":"J Clin Oncol"},{"key":"BFbmt201723_CR26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/bmt.2014.255","volume":"50","author":"HW Auner","year":"2015","unstructured":"Auner HW, Szydlo R, Hoek J, Goldschmidt H, Stoppa AM, Morgan GJ et al. Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transplant 2015; 50: 209\u2013215.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201723_CR27","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.3324\/haematol.13273","volume":"93","author":"E Jantunen","year":"2008","unstructured":"Jantunen E, Canals C, Rambaldi A, Ossenkoppele G, Allione B, Blaise D et al. Autologous stem cell transplantation in elderly patients (> or =60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry. Haematologica 2008; 93: 1837\u20131842.","journal-title":"Haematologica"},{"key":"BFbmt201723_CR28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3324\/haematol.10552","volume":"92","author":"X Thomas","year":"2007","unstructured":"Thomas X, Suciu S, Rio B, Leone G, Broccia G . Fillet G, et al. Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC-GIMEMA AML-13 study. Haematologica 2007; 92: 389\u2013396.","journal-title":"Haematologica"},{"key":"BFbmt201723_CR29","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1038\/bmt.2010.289","volume":"46","author":"DJ Andorsky","year":"2011","unstructured":"Andorsky DJ, Cohen M, Naeim A, Pinter-Brown L . Outcomes of auto-SCT for lymphoma in subjects aged 70 years and over. Bone Marrow Transplant 2011; 46: 1219\u20131225.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201723_CR30","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/ajh.23108","volume":"87","author":"RL Elstrom","year":"2012","unstructured":"Elstrom RL, Martin P, Hurtado Rua S, Shore TB, Furman RR, Ruan J et al. Autologous stem cell transplant is feasible in very elderly patients with lymphoma and limited comorbidity. Am J Hematol 2012; 87: 433\u2013435.","journal-title":"Am J Hematol"},{"key":"BFbmt201723_CR31","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.bbmt.2014.01.025","volume":"20","author":"D Chihara","year":"2014","unstructured":"Chihara D, Izutsu K, Kondo E, Sakai R, Mizuta S, Yokoyama K et al. High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed\/refractory diffuse large B cell lymphoma: a nationwide retrospective study. Biol Blood Marrow Transplant 2014; 20: 684\u2013689.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201723_CR32","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1093\/annonc\/mdv018","volume":"26","author":"VA Morrison","year":"2015","unstructured":"Morrison VA, Hamlin P, Soubeyran P, Stauder R, Wadhwa P, Aapro M et al. Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary. Ann Oncol 2015; 26: 1058\u20131068.","journal-title":"Ann Oncol"},{"key":"BFbmt201723_CR33","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.bbmt.2008.05.002","volume":"14","author":"TM Wildes","year":"2008","unstructured":"Wildes TM, Augustin KM, Sempek D, Zhang QJ, Vij R, Dipersio JF et al. Comorbidities, not age, impact outcomes in autologous stem cell transplant for relapsed non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 840\u2013846.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFbmt201723_CR34","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J, Gold J . Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245\u20131251.","journal-title":"J Clin Epidemiol"},{"key":"BFbmt201723_CR35","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1200\/JCO.2011.34.7625","volume":"29","author":"A Hurria","year":"2011","unstructured":"Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 2011; 29: 3457\u20133465.","journal-title":"J Clin Oncol"},{"key":"BFbmt201723_CR36","doi-asserted-by":"publisher","first-page":"e437","DOI":"10.1016\/S1470-2045(12)70259-0","volume":"13","author":"ME Hamaker","year":"2012","unstructured":"Hamaker ME, Jonker JM, de Rooij SE, Vos AG, Smorenburg CH, van Munster BC . Frailty screening methods for predicting outcome of a comprehensive geriatric assessment in elderly patients with cancer: a systematic review. Lancet Oncol 2012; 13: e437\u2013e444.","journal-title":"Lancet Oncol"},{"key":"BFbmt201723_CR37","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","volume":"125","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Bringhen S, Mateos M-V, Larocca A, Facon T, Kumar SK et al. Geriatric assessment predicts survival and toxicities in elderly myeloma: an International Myeloma Working Group report. Blood 2015; 125: 2068\u20132074.","journal-title":"Blood"},{"key":"BFbmt201723_CR38","doi-asserted-by":"publisher","first-page":"4151","DOI":"10.1200\/JCO.2003.05.024","volume":"21","author":"LE Abrey","year":"2003","unstructured":"Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003; 21: 4151\u20134156.","journal-title":"J Clin Oncol"},{"key":"BFbmt201723_CR39","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/sj.bmt.1705452","volume":"38","author":"P Colombat","year":"2006","unstructured":"Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study ofthe GOELAMS group. Bone Marrow Transplant 2006; 38: 417\u2013420.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201723_CR40","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/annonc\/mdl458","volume":"18","author":"M Montemurro","year":"2007","unstructured":"Montemurro M, Kiefer T, Schuler F, Al-Ali HK, Wolf HH, Herbst R et al. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan\/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. Ann Oncol 2007; 18: 665\u2013671.","journal-title":"Ann Oncol"},{"key":"BFbmt201723_CR41","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s12185-014-1608-9","volume":"100","author":"K Miyao","year":"2014","unstructured":"Miyao K, Sakemura R, Imai K, Sakai T, Tsushita N, Kato T et al. Upfront autologous stem-cell transplantation with melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) in patients with newly diagnosed primary central nervous system lymphoma. Int J Hematol 2014; 100: 152\u2013158.","journal-title":"Int J Hematol"},{"key":"BFbmt201723_CR42","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1093\/annonc\/mds059","volume":"23","author":"B Kasenda","year":"2012","unstructured":"Kasenda B, Schorb E, Fritsch K, Finke J, Illerhaus G . Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma\u2014a long-term follow-up study. Ann Oncol 2012; 23: 2670\u20132675.","journal-title":"Ann Oncol"},{"key":"BFbmt201723_CR43","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/bmt.2010.71","volume":"46","author":"DH Yoon","year":"2011","unstructured":"Yoon DH, Lee DH, Choi DR, Sohn BS, Kim S, Kim SW et al. Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience. Bone Marrow Transplant 2011; 46: 105\u2013109.","journal-title":"Bone Marrow Transplant"},{"key":"BFbmt201723_CR44","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1600-0609.2005.00508.x","volume":"75","author":"M Brevet","year":"2005","unstructured":"Brevet M, Garidi R, Gruson B, Royer B, Vaida I, Damaj G . First-line autologous transplantation in stem cell primary CNS lymphoma. Eur J Haematol 2005; 75: 288\u2013292.","journal-title":"Eur J Haematol"},{"key":"BFbmt201723_CR45","doi-asserted-by":"publisher","first-page":"862","DOI":"10.3109\/10428194.2011.633250","volume":"53","author":"N Alimohamed","year":"2012","unstructured":"Alimohamed N, Daly A, Owen C, Duggan P, Stewart DA . Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience. Leuk Lymphoma 2012; 53: 862\u2013867.","journal-title":"Leuk Lymphoma"},{"key":"BFbmt201723_CR46","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s12185-013-1403-z","volume":"98","author":"MK Choi","year":"2013","unstructured":"Choi MK, Kang ES, Kim DW, Ko YH, Seok H, Park JH et al. Treatment outcome of relapsed\/refractory primary central nervous system diffuse large B-cell lymphoma: a single-center experience of autologous stem cell transplantation. Int J Hematol 2013; 98: 346\u2013354.","journal-title":"Int J Hematol"},{"key":"BFbmt201723_CR47","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1200\/JCO.2001.19.3.742","volume":"19","author":"C Soussain","year":"2001","unstructured":"Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001; 19: 742\u2013749.","journal-title":"J Clin Oncol"},{"key":"BFbmt201723_CR48","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3109\/10428194.2014.916800","volume":"56","author":"MR Welch","year":"2015","unstructured":"Welch MR, Sauter CS, Matasar MJ, Faivre G, Weaver SA, Moskowitz CH et al. Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide. Leuk Lymphoma 2015; 56: 361\u2013367.","journal-title":"Leuk Lymphoma"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bmt201723.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201723","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/bmt.2017.23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/bmt201723.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T19:16:50Z","timestamp":1648063010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bmt201723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,24]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["BFbmt201723"],"URL":"https:\/\/doi.org\/10.1038\/bmt.2017.23","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,24]]},"assertion":[{"value":"19 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}